@article{889be848efea4032b07238675646f5dc,
title = "Management of cytokine release syndrome: An update on emerging antigen-specific T cell engaging immunotherapies",
keywords = "BiTE, CAR T cells, CRS, bispecific T cell engager, chimeric antigen receptor, cytokine release syndrome, immunotherapy, neurotoxicity",
author = "Khadka, {Roman H.} and Reona Sakemura and Kenderian, {Saad S.} and Johnson, {Aaron J.}",
note = "Funding Information: This work was supported by R01 NS 103212. SS Kenderian is an inventor on patents in the field of CART cell therapy that are licensed to Novartis (under an agreement between Mayo Clinic, University of Pennsylvania, and Novartis). SS Kenderian{\textquoteright}s laboratory receives research funding from Kite, Gilead, Novartis, Humanigen, Tolero, Lentigen, and Morphosys. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.",
year = "2019",
doi = "10.2217/imt-2019-0074",
language = "English (US)",
volume = "11",
pages = "851--857",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "10",
}